Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran

References

• TuzmenSTuzmenPAroraSMoussesSRNAi-based functional pharmacogenomicsMethods Mol Biol201170027129021204040
   PubMedGoogle Scholar
• ElbashirSMHarborthJWeberKTuschlTAnalysis of gene function in somatic mammalian cells using small interfering RNAsMethods200226219921312054897
   PubMed Web of Science ®Google Scholar
• FireAXuSMontgomeryMKKostasSADriverSEMelloCCPotent and specific genetic interference by double-stranded RNA in Caenorhabditis elegansNature199839166698068119486653
   PubMed Web of Science ®Google Scholar
• HannonGJRNA interferenceNature2002418689424425112110901
   PubMed Web of Science ®Google Scholar
• HuppiKMartinSECaplenNJDefining and assaying RNAi in mammalian cellsMol Cell200517111015629712
   PubMed Web of Science ®Google Scholar
• TuschlTRNA interference and small interfering RNAsChembiochem20012423924511828450
   PubMed Web of Science ®Google Scholar
• NakayashikiHNguyenQBRNA interference: roles in fungal biologyCurr Opin Microbiol200811649450218955156
   PubMed Web of Science ®Google Scholar
• TravellaSKellerBDown-regulation of gene expression by RNA-induced gene silencingMethods Mol Biol200947818519919009447
   PubMedGoogle Scholar
• BernsteinECaudyAAHammondSMHannonGJRole of a bidentate ribonuclease in the initiation step of RNA interferenceNature2001409681836336611201747
   PubMed Web of Science ®Google Scholar
• FilipowiczWRNAi: the nuts and bolts of the RISC machineCell20051221172016009129
   PubMed Web of Science ®Google Scholar
• HemannMTFridmanJSZilfouJTAn epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivoNat Genet200333339640012567186
   PubMed Web of Science ®Google Scholar
• CarmellMAZhangLConklinDSHannonGJRosenquistTAGermline transmission of RNAi in miceNat Struct Biol2003102919212536207
   PubMedGoogle Scholar
• TiscorniaGSingerOIkawaMVermaIMA general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNAProc Natl Acad Sci U S A200310041844184812552109
   PubMed Web of Science ®Google Scholar
• CaplenNJRNAi as a gene therapy approachExpert Opin Biol Ther20033457558612831363
   PubMed Web of Science ®Google Scholar
• WildaMFuchsUWossmannWBorkhardtAKilling of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)Oncogene200221375716572412173041
   PubMed Web of Science ®Google Scholar
• BrummelkampTRBernardsRAgamiRStable suppression of tumorigenicity by virus-mediated RNA interferenceCancer Cell20022324324712242156
   PubMed Web of Science ®Google Scholar
• ScherrMBattmerKWinklerTHeidenreichOGanserAEderMSpecific inhibition of bcr-abl gene expression by small interfering RNABlood200310141566156912393533
   PubMed Web of Science ®Google Scholar
• SonYATüzmenŞHızelCDesigning and implementing pharmacogenomics studyBarhDDhawanDNirmal KumarGOmics for Personalized MedicineNew DelhiSpringer201397122
   Google Scholar
• SongELeeSKWangJRNA interference targeting Fas protects mice from fulminant hepatitisNat Med20039334735112579197
   PubMed Web of Science ®Google Scholar
• DavisMEThe first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinicMol Pharm20096365966819267452
   PubMed Web of Science ®Google Scholar
• LorenzerCDirinMWinklerAMBaumannVWinklerJGoing beyond the liver: progress and challenges of targeted delivery of siRNA therapeuticsJ Control Release201520311525660205
   PubMed Web of Science ®Google Scholar
• VicentiniFTBorgheti-CardosoLNDepieriLVDelivery Systems and Local Administration Routes for Therapeutic siRNAPharm Res201330491593123344907
   PubMed Web of Science ®Google Scholar
• TTR geneGenetic Home reference2009 Available from: http://ghr.nlm.nih.gov/gene/TTRAccessed June 16, 2017
   Google Scholar
• NCBITTR transthyretin [Homo sapiens (human)]2015 Available from: http://www.ncbi.nlm.nih.gov/gene/7276Accessed June 16, 2017
   Google Scholar
• Online Mendelian Inheritance in ManTransthyretin; TTR Available from: http://www.omim.org/entry/176300Accessed June 16, 2017
   Google Scholar
• Gene CardsTTR gene Available from: http://www.genecards.org/cgi-bin/carddisp.pl?gene=TTRAccessed June 16, 2017
   Google Scholar
• ConnorsLHLimAProkaevaTRoskensVACostelloCETabulation of human transthyretin (TTR) variants, 2003Amyloid200310316018414640030
   PubMed Web of Science ®Google Scholar
• NakazatoMGenotype-phenotype relationship in familial amyloid polyneuropathyNeurol Med (Tokyo)199848528534
   Google Scholar
• BensonMDAmyloidosisScriverCRBeaudetALSlyWSValleDThe Metabolic and Molecular Bases of Inherited Diseases8th ed4New YorkMcGraw-Hill200153455378
   Google Scholar
• SaraivaMJTransthyretin mutations in hyperthyroxinemia and amyloid diseasesHum Mutat200117649350311385707
   PubMed Web of Science ®Google Scholar
• NOVANEXT [webpage on the Internet]RNAi Therapies-Cure or Chimaera? Available from http://www.pbs.org/wgbh/nova/next/body/rnai/Accessed July 11, 2017
   Google Scholar
• RubergFLBerkJLTransthyretin (TTR) cardiac amyloidosisCirculation2012126101286130022949539
   PubMed Web of Science ®Google Scholar
• RappleyIMonteiroCNovaisMQuantification of transthyretin kinetic stability in human plasma using subunit exchangeBiochemistry201453121993200624661308
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals, IncAlnylam Pharmaceuticals discontinues revusiran development2016 Available from: http://investors.alnylam.com/releasedetail.cfm?ReleaseID=992320Accessed June 16, 2017
   Google Scholar
• Munar-QuésMSaraivaMJCalongeJOFamilial amyloid polyneuropathy in a Spanish family with a transthyretin deletion (deltaVal 122) presenting with carpal tunnel syndromeClin Genet200058541141211140845
   PubMed Web of Science ®Google Scholar
• BurtonCChestertonLSDavenportGDiagnosing and managing carpal tunnel syndrome in primary careBr J Gen Pract20146462226226324771836
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and StrokeCarpal tunnel syndrome fact sheet Available from: http://www.ninds.nih.gov/disorders/carpal_tunnel/detail_carpal_tunnel.htmAccessed June 16, 2017
   Google Scholar
• WebMDCarpal tunnel syndrome – topic overview2014 Available from: http://www.webmd.com/pain-management/carpal-tunnel/carpal-tunnel-syndrome-topic-overview#1Accessed July 11, 2017
   Google Scholar
• ShielWCFACPCarpal tunnel syndrome symptoms, tests and diagnosis Available from: http://www.medicinenet.com/carpal_tunnel_syndrome/article.htm
   Google Scholar
• National Center for Biotechnology InformationSH3TC2 SH3 domain and tetratricopeptide repeats 2 [Homo sapiens (human)] Available from: http://www.ncbi.nlm.nih.gov/gene/79628Accessed June 16, 2017
   Google Scholar
• AlnylamHereditary ATTR amyloidosis with polyneuropathy (hATTR-PN) Available from: http://alnylam.microartswpdev.com/product-pipeline/hereditary-attr-amyloidosis-with-polyneuropathy/Accessed July 12, 2017
   Google Scholar
• OMIMAmyloidosis, hereditary, transthyretin-related2016 Available from: https://www.omim.org/entry/105210Accessed July 12, 2017
   Google Scholar
• XuJYangMPanXTransthyretin-related hereditary amyloidosis with recurrent vomiting and renal insufficiency as the initial presentation: a case reportMedicine20179610e573728272196
   PubMed Web of Science ®Google Scholar
• MedscapeTransthyretin-related amyloidosis2017 Available from: http://emedicine.medscape.com/article/335301-overviewAccessed July 11, 2017
   Google Scholar
• AdamsDRecent advances in the treatment of familial amyloid poly-neuropathyTher Adv Neurol Disord20136212913923483184
   PubMed Web of Science ®Google Scholar
• Amyloidosis Patient Information SiteATTR amyloidosis Available from: http://www.amyloidosis.org.uk/introduction-to-attr-amyloidosis/Accessed June 16, 2017
   Google Scholar
• MedscapeTransthyretin-related amyloidosis workup2017 Available from: http://emedicine.medscape.com/article/335301-workup#c6Accessed July 12, 2017
   Google Scholar
• AndoYUedaMDiagnosis and therapeutic approaches to transthyretin amyloidosisCurr Med Chem201219152312232322471980
   PubMed Web of Science ®Google Scholar
• GertzMARajkumarVSAmyloidosis: Diagnosis and TreatmentSpringer Science & Business Media2010
   Google Scholar
• AdamsDSuhrOBHundEEuropean Network for TTR-FAP (ATTReuNET)First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathyCurr Opin Neurol201629Suppl 1S14S2626734952
   PubMed Web of Science ®Google Scholar
• HistalimHematoxylin eosin saffron Available from: http://www.histalim.com/accueil/activities/our-services/histology/hematoxylin-eosin-saffron/Accessed June 16, 2017
   Google Scholar
• Surgical pathology – histology. Staining manual – connective tissue Collagen – Masson’s Trichrome stain (TRI) Available from: http://library.med.utah.edu/WebPath/HISTHTML/MANUALS/MASSONS.PDFAccessed June 16, 2017
   Google Scholar
• Surgical pathology – histology. Staining manual – connective tissue. Elastic tissue fibers – Verhoeff’s Van Gieson (EVG) Available from: http://library.med.utah.edu/WebPath/HISTHTML/MANUALS/EVG.PDFAccessed June 16, 2017
   Google Scholar
• SereikaiteJBumelisVACongo red interaction with alpha-proteinsActa Biochim Pol2006531879216565748
   PubMed Web of Science ®Google Scholar
• MedscapeTransthyretin-related amyloidosis treatment & management2017 Available from: http://emedicine.medscape.com/article/335301-treatmentAccessed July 12, 2017
   Google Scholar
• AdamsDSamuelDGoulon-GoeauCThe course and prognostic factors of familial amyloid polyneuropathy after liver transplantationBrain2000123Pt 71495150410869060
   PubMed Web of Science ®Google Scholar
• AlnylamOur culture Available from: http://www.alnylam.com/who-we-are/our-culture/Accessed June 16, 2017
   Google Scholar
• ZhouJShumKTBurnettJRossiJNanoparticle-based delivery of RNAi therapeutics: progress and challengesPharmaceuticals (Basel)2013618510723667320
   PubMedGoogle Scholar
• TamYYChenSCullisPRAdvances in lipid nanoparticles for siRNA deliveryPharmaceutics20135349850724300520
   PubMedGoogle Scholar
• HuangLLiuYIn vivo delivery of RNAi with lipid-based nanoparticlesAnnu Rev Biomed Eng20111350753021639780
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals, IncAlnylam acquires investigational RNAi therapeutic assets from Merck2014 Available from: http://investors.alnylam.com/releasedetail.cfm?ReleaseID=818732Accessed June 16, 2017
   Google Scholar
• BurnettJCRossiJJTiemannKCurrent progress of siRNA/shRNA therapeutics in clinical trialsBiotechnol J2011691130114621744502
   PubMed Web of Science ®Google Scholar
• NguyenTMenocalEMHarborthJFruehaufJHRNAi therapeutics: an update on deliveryCurr Opin Mol Ther200810215816718386228
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals, IncAlnylam presents key scientific data on enhanced stabilization chemistry (ESC)-GalNAc-conjugate technology2014 Available from: http://investors.alnylam.com/releasedetail.cfm?ReleaseID=846985Accessed June 16, 2017
   Google Scholar
• Alnylam PharmaceuticalsRNAi Roundtable: Patrisiran and ALN-TTRsc in Development for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR) Available from http://www.alnylam.com/web/assets/RNAi_Roundtable_TTR_071514.pdfAccessed September 25, 2017
   Google Scholar
• GalNAc-siRNA with enhanced stabilization chemistry: ESC-GalNAc-siRNA2014 Available from: http://www.alnylam.com/web/assets/ALNY-ESC-GalNAc-siRNA-TIDES-May2014-Capella.pdfAccessed June 16, 2017
   Google Scholar
• CarthewRWSontheimerEJOrigins and mechanisms of miRNAs and siRNAsCell2009136464265519239886
   PubMed Web of Science ®Google Scholar
• CoelhoTAdamsDSilvaASafety and efficacy of RNAi therapy for transthyretin amyloidosisN Engl J Med2013369981982923984729
   PubMed Web of Science ®Google Scholar
• Alnylam Pharmaceuticals2014 Available from: http://www.alnylam.com/web/assets/072214Alnylam.pdfAccessed June 16, 2017
   Google Scholar
• Mayo ClinicAPOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Available from: http://test.kcms.mayoclinic.org/research/clinical-trials/cls-20115984Accessed June 16, 2017
   Google Scholar
• Alnylam Presents Positive Preliminary Clinical Results for ALN-ttr01. Alnylam Pharmaceuticals, Inc. - Alnylam Presents Key Scientific Data on Enhanced Stabilization Chemistry (ESC)-GalNAc-Conjugate Technology Available from http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734340Accessed July 12,2017
   Google Scholar
• RNAi TherapeuticsInternational Symposium on Familial Amyloidotic Polyneuropathy Clinical Updates on ALN-TTR Programs Patisiran (ALN-TTR02) and ALN-TTRsc for the Treatment of Transthyretin Amyloidosis2013 Available from: http://www.alnylam.com/web/wp-content/uploads/2013/11/ALNY-ISFAP-ALN-TTRprogram-Nov2013.pdfAccessed June 16, 2017
   Google Scholar
• Alnylam PharmaceuticalsPositive phase II data with Patisiran (ALN-TTR02) Available from: http://www.alnylam.com/capella/presentations/positive-phase-ii-data-patisiran-isfap/Accessed June 16, 2017
   Google Scholar
• Alnylam Pharmaceuticals, IncAlnylam reports positive phase II data for Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), and initiates phase III trial [press release]CambridgeAlnylam Pharmaceuticals20131110
   Google Scholar
• SuhrOClinical update on Patisiran phase 2 trials in familial amyloidotic polyneuropathy2014 Available from: http://www.alnylam.com/web/assets/ALNY-Clinical-Update-Patisiran-Phase2-Trials-ISA2014.pdfAccessed July 12, 2017
   Google Scholar
• GardeDAlnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)FierceBiotech Available from http://www.fiercebiotech.com/biotech/alnylam-reports-six-month-clinical-data-from-patisiran-phase-2-open-label-extension-ole. Published October 13, 2014Accessed July 11, 2017
   Google Scholar
• Alnylam PharmaceuticalsTTR amyloidosis (FAP) Available from: http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap/Accessed July 11, 2017
   Google Scholar
• VieiraMSaraivaMJTransthyretin: a multifaceted proteinBiomol Concepts201451455425372741
   PubMedGoogle Scholar
• NakagawaMSakijimaYYazakiMCarpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosisAmyloid2016231586326852880
   PubMed Web of Science ®Google Scholar
• AlshehriBD’SouzaDGLeeJYPetratosSRichardsonSJThe diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruptionJ Neuroendocrinol201527530332325737004
   PubMed Web of Science ®Google Scholar
• WestermarkPAspects on human amyloid forms and their fibril polypeptidesFEBS J20152722359425949
   Web of Science ®Google Scholar
• EriczonBGWilczekHELarssonMLiver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?Transplantation20159991847185426308415
   PubMed Web of Science ®Google Scholar
• BulawaCEConnellySDevitMTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProc Natl Acad Sci U S A2012109249629963422645360
   PubMed Web of Science ®Google Scholar
• AlmeidaMRMacedoBCardosoISelective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivativeBiochem J2005381Pt 2351356
   Google Scholar
• CruzMWBensonMDA review of tafamidis for the treatment of transthyretin-related amyloidosisNeurol Ther201542617926662359
   PubMedGoogle Scholar
• IONIS-TTRRXIONIS-TTRRx clinical trials Available from: http://ttrstudy.com/ionis-ttrrx-clinical-trials/Accessed June 16, 2017
   Google Scholar
• Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis. (NASDAQ:PRTA) Available from http://ir.prothena.com/releasedetail.cfm?releaseid=978092Accessed July 11, 2017
   Google Scholar
• TengMHYinJYVidalRAmyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosisLab Invest200181338539611310831
   PubMed Web of Science ®Google Scholar
• YokoyamaTHanawaYObitaTMizuguchiMStability and crystal structures of His88 mutant human transthyretinsFEBS Lett Epub2017531
   Web of Science ®Google Scholar
• LiepnieksJJBensonMDProgression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantationAmyloid200714427728217968687
   PubMed Web of Science ®Google Scholar
• GillmoreJDMaurerMSFalkRHNonbiopsy diagnosis of cardiac transthyretin amyloidosisCirculation2016133242404241227143678
   PubMed Web of Science ®Google Scholar
• RCSB PDB https://www.rcsb.org/pdb/explore/remediatedSequence.do?structureId=5TZL of PDB ID 5TZL
   Google Scholar
  KabschWSanderC1983Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical featuresBiopolymers2212257726376667333
   PubMed Web of Science ®Google Scholar